Decision/Conclude agreement
Proposed

方達控股目標業務出售予Charles River Laboratories

Tigermed's privatization of Frontage Holdings splits its business, with the bioanalytical and DMPK target business to be sold to Charles River Laboratories at a preliminary valuation of about US$470 million.

Trajectories

Mine up to three arcs for this record — target, direction, probability, horizon.

Actors and targets

Targets Charles River Laboratoriesactor生物分析及藥物代謝動力學(DMPK)等目標業務item

Source

生物分析及藥物代謝動力學(DMPK)等目標業務將出售予Charles River Laboratories,初步估值約4.7億美元
stockintelligencenews · Telegram Open post

Extracted detail

Bank
瑞銀
Currency
USD

Related decisions